Literature DB >> 6121443

Tiapride in the treatment of tardive dyskinesia.

O J Buruma, R A Roos, G W Bruyn, B Kemp, E A van der Velde.   

Abstract

The effect of Tiapride on dyskinesia was evaluated in 12 patients with tardive dyskinesia in a double-blind controlled cross-over trial. The effect was measured by a Doppler-radar device and by counting the number of involuntary movements from video-recordings. Besides these methods, subjective assessments were made on analogue scales by family, nurses and attendant doctors. The subjective evaluation appeared to be useless because of many inconsistent answers. The quantitative methods revealed a significant diminution of the involuntary movements in the Tiapride therapy period (P less than 0.01). It appears that tiapride is an effective drug in the treatment of tardive dyskinesia. No clinically important side-effects have been observed. The drug appeared not to induce parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6121443     DOI: 10.1111/j.1600-0404.1982.tb03059.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  8 in total

Review 1.  Antipsychotic medication for elderly people with schizophrenia.

Authors:  R G Marriott; W Neil; S Waddingham
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

2.  Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease.

Authors:  T Norman; E Chiu; R H James; M S Gregory
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Pharmacokinetics of tiapride in patients with tardive dyskinesia and Huntington's disease.

Authors:  R A Roos; E J de Haas; O J Buruma; F A de Wolff
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Assessment of the therapeutic range of tiapride in patients with tardive dyskinesia.

Authors:  R A Roos; E A Van der Velde; O J Buruma; F A de Wolff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-09       Impact factor: 10.154

5.  The antidyskinetic action of dihomo-gamma-linolenic acid in the rodent.

Authors:  B Costall; M E Kelly; R J Naylor
Journal:  Br J Pharmacol       Date:  1984-11       Impact factor: 8.739

6.  Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia.

Authors:  U Andersson; J E Häggström; M I Nilsson; E Widerlöv
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 7.  Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.

Authors:  Hanna Bergman; John Rathbone; Vivek Agarwal; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06

Review 8.  Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.

Authors:  Hany G El-Sayeh; John Rathbone; Karla Soares-Weiser; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-01-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.